Aptus will follow their Cancer Treatment program with AptaGastro (IDI-20230064) financed by ISCIII and CDTI with funds from the European Union’s Recovery and Resilience Mechanism, in the call for R&D+I projects related to personalized medicine and advanced therapies

AptaGastro project aims to validate the use of the apMNKQ2 aptamer as a potential antitumor drug in gastrointestinal cancers, specifically pancreatic adenocarcinoma (PCA) and colorectal cancer (CRC). This project is carried out in collaboration with IRYCIS and UAM.